Genmab — November 2017
-
In summary, we found daratumumab is a highly effective novel monotherapy for T-ALL in preclinical models. Based on this work, we are planning to open a multi-institutional early phase clinical trial for children and young adults with relapsed and refractory T-ALL.https://ash.confex.com/ash/2017/webprogram/Paper101472.html
-
Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies
Abstract # 1495
Saturday, December 9, 5:30 - 7:30 p.m. ET -
today announced that Phase 1 data on flotetuzumab, MacroGenics' CD123 x CD3 bispecific DART
molecule, will be featured in three presentations, including an oral session, at the 59th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta on December 9-12, 2017. -
-
ADCT 301. Nu = Camidanlumab Tesirine !!! pts with HL have been treated with doses ≥30 µg/kg, with an ORR of 63.6% (14/22) and a complete response rate of 27.3% (6/22); ORRs by prior treatment were: 13/21 (61.9%) pts who previously received brentuximab vedotin (BV), 10/16 (62.5%) pts who previously received a checkpoint inhibitor and BV
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind